Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Carol, Koro"'
Autor:
Yu Yang, Liang Zhang, Susanne Hartwig, Peng Jiang, Houyu Zhao, Ruogu Meng, Zhike Liu, Zuoxiang Liu, Keqin Ding, Xuedan You, Carol Koro, Guozhang Xu, Siyan Zhan
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
The 4-valent (4 v) and 9-valent (9 v) human papillomavirus (HPV) vaccines are approved in China for females aged 9–45 years. However, the real-world impact of 4vHPV or 9vHPV vaccination for the prevention of high-grade cervical disease in Chinese w
Externí odkaz:
https://doaj.org/article/d7cccfcf4f344d8db5b9d9bc82fa8d22
Autor:
Jiangrong Wang, Eva Herweijer, Sara Nordqvist Kleppe, Susanne Hartwig, Christine Velicer, Carol Koro, Karin Sundström
Publikováno v:
Preventive Medicine Reports, Vol 35, Iss , Pp 102342- (2023)
Background: Close monitoring of vaccination coverage is important for cervical cancer prevention efforts. The study aims to describe the HPV vaccination coverage by dose in girls eligible for HPV vaccination within Sweden’s childhood immunization p
Externí odkaz:
https://doaj.org/article/e5cac48cf26c4690a46df1a460f3f60e
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss 3, Pp 251-256 (2020)
Abstract Background BRIDION® (sugammadex sodium) is an agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium and vecuronium in general anesthesia. Following the approval of sugammadex in Canada (February 2016), Health Canada r
Externí odkaz:
https://doaj.org/article/51f892da21204fd38d7af05c92ce1e38
Autor:
Carol Koro, Kerstin Becker, Julia DiBello, Anja Bauerfeind, Suzanne Reed, Klaas Heinemann, Christian Franke
Publikováno v:
The European Journal of Contraception & Reproductive Health Care. 26:439-446
Objective To assess and compare the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) in NOMAC-E2 users with levonorgestrel-containing combined oral contraceptive (COCLNG) users. Study design This large, prospective, observation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d4f8a337be6d499be46c32dce1d510b
https://doi.org/10.1080/13625187.2021.1987410
https://doi.org/10.1080/13625187.2021.1987410
Publikováno v:
Contraception. 120:109920
To monitor pregnancy occurrence and outcomes among Nexplanon users in the United States during standard clinical practice.The Nexplanon Observational Risk Assessment (NORA) study was a large prospective cohort study conducted in the United States (US
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7210a6e5ce96fb69e57391e51ceb149
https://doi.org/10.1016/j.contraception.2022.109920
https://doi.org/10.1016/j.contraception.2022.109920
Publikováno v:
Drugs-Real World Outcomes, Vol 7, Iss 3, Pp 251-256 (2020)
Drugs-Real World Outcomes
Drugs-Real World Outcomes
Background BRIDION® (sugammadex sodium) is an agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium and vecuronium in general anesthesia. Following the approval of sugammadex in Canada (February 2016), Health Canada required a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6754bff524c6b052442392c7394bdb3
https://doi.org/10.1007/s40801-020-00200-z
https://doi.org/10.1007/s40801-020-00200-z
Publikováno v:
Hosp Pharm
Background: Sugammadex (Bridion) was approved by the US Food and Drug Administration (FDA) in December 2015 for the reversal of neuromuscular block (NMB) induced by rocuronium and vecuronium bromide in adults undergoing surgery and approved for use i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e4448ffa72c748accd54915f2b03914
https://doi.org/10.1177/0018578720918332
https://doi.org/10.1177/0018578720918332
Autor:
Carol Koro, Anne Hickman, Tongtong Wang, Philip LStJ Jones, Shrita Patel, Xinyue Liu, Ira Gantz
Publikováno v:
Diabetes Therapy
Diabetes Therapy, Vol 11, Iss 3, Pp 711-723 (2020)
Diabetes Therapy, Vol 11, Iss 3, Pp 711-723 (2020)
Introduction Based on post-marketing surveillance, concern has been raised that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may increase the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene, FG). As a result of the low in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3b10fe33cfc2263b091852a7a7a1d91
https://doi.org/10.1007/s13300-020-00771-8
https://doi.org/10.1007/s13300-020-00771-8
Autor:
Wei (Vivian) Wang, Smita Kothari, Jozica Skufca, Anna R. Giuliano, Karin Sundström, Mari Nygård, Carol Koro, Marc Baay, Thomas Verstraeten, Alain Luxembourg, Alfred J. Saah, Suzanne M. Garland
Human papillomavirus (HPV) infection, which poses significant disease burden, is decreasing following implementation of vaccination programs. Synthesized evidence on HPV vaccine real-world benefit was published in 2016. However, long-term impact of v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df9b350dd9c90101f6102ba9cf231fd
Publikováno v:
Contraception. 100(1)
Objectives We conducted this study to characterize the frequency of insertion-, localization- and removal-related events and their clinically significant consequences among Nexplanon® (etonogestrel radiopaque contraceptive implant) users in the Unit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65cb050f0c8f224406b67f42d9618186
https://pubmed.ncbi.nlm.nih.gov/30980829
https://pubmed.ncbi.nlm.nih.gov/30980829